MedPath

Postoperative Analgesic Effect of Nefopam

Not Applicable
Completed
Conditions
Stomach Neoplasms
Interventions
Drug: Saline
Registration Number
NCT02561494
Lead Sponsor
Seoul National University Bundang Hospital
Brief Summary

Nefopam will be administered to the patients undergoing laparoscopic gastrectomy under the total intravenous anesthesia (TIVA).

The investigators will evaluate whether the nefopam can decrease the total amount of remifentanil administered during the operation, which will reduce the acute opioid tolerance and following consumption of fentanyl during postoperative period.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
78
Inclusion Criteria
  • Early or advanced gastric cancer
Exclusion Criteria
  • Refusal
  • Use of preoperative analgesic drugs
  • Pregnancy
  • Recurred gastric cancer
  • Seizure
  • Cardiac disease
  • Monoamine oxidase inhibitor
  • Urologic disease
  • Previous intrabdominal surgery
  • Body mass index > 30 or < 16

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlSalineIntravenous normal saline 2 ml is given slowly as a placebo before the anesthesia induction and after finishing anesthesia.
NefopamNefopamIntravenous nefopam 20 mg is given slowly before the anesthesia induction and after finishing anesthesia.
Primary Outcome Measures
NameTimeMethod
Change of the administered fentanyl dose from postoperative 6 h to postoperative 5 daypostoperative 6 h, postoperative 1 day, postoperative 2 day, postoperative 3 day, postoperative 5 day
Secondary Outcome Measures
NameTimeMethod
Change of the pain score from postoperative 6 h to postoperative 5 daypostoperative 6 h, postoperative 1 day, postoperative 2 day, postoperative 3 day, postoperative 5 day

Trial Locations

Locations (1)

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Gyeonggi, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath